Search the Newsreel

Helix BioPharma Reshapes Board to Align with Oncology Growth Strategy

(PHAR) and the Role of Price-Sensitive Allocations

This article provides an AI-driven analysis of Pharming Group N.v. (NASDAQ: PHAR), highlighting a near-term strong sentiment potentially challenging mid- and long-term weakness. It outlines specific institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis, to assist investors …

Helix Biopharma Corp. Announces Board Composition Changes

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint, Inc. announced the granting of non-statutory stock options to two new employees as inducement awards, in accordance with NASDAQ Listing Rule 5635(c)(4). These options allow the purchase of up to 14,600 shares of common stock, with an exercise price of $14.75 per share, …

Vor Biopharma (VOR) sees Venrock-led group report 9.99% ownership stake

A Venrock-led group, including Venrock Healthcare Capital and individuals Nimish Shah and Bong Koh, has reported a beneficial ownership stake of 9.99% in Vor Biopharma Inc. (VOR). This stake comprises 5,676,370 shares of common stock, including Pre-Funded Warrants, as of June 30, 2026. A …

Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights

Traws Pharma announced its Q2 2026 financial results, highlighting progress in advancing tivoxavir marboxil towards MHRA resubmission in Q3 2026 for its influenza challenge study, despite a U.S. FDA clinical hold. The company also detailed its April 2026 private placement, which secured $10 million …

Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax

Supernus Pharmaceuticals' Chief Medical Officer, Jonathan Rubin, exercised 750 Performance Share Units (PSUs) on August 12, 2026, converting them into 750 shares of common stock. To cover tax withholding requirements associated with this vesting, 363 shares were withheld by the company at a price …

Sutro Biopharma (STRO): Perceptive Advisors reports 7.9% beneficial stake

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 7.9% of Sutro Biopharma's common stock, totaling 1,304,846 shares. This ownership is based on 16,572,171 shares outstanding as of August 7, 2026. The reporting persons have …

Eloxx Pharmaceuticals (ELOX) stake hits 9.99% for Samsara affiliate

Investment entities affiliated with Samsara BioCapital and Srinivas Akkaraju have reported significant beneficial ownership in Eloxx Pharmaceuticals (ELOX). Dr. Srinivas Akkaraju holds 9.99% of the common stock, while each Samsara BioCapital-affiliated entity owns 5.0%. This includes common shares and Pre-Funded Warrants subject to a …

Perceptive Advisors (XFOR) reports 8.1% beneficial stake in X4 Pharmaceuticals

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have collectively reported an 8.1% beneficial ownership stake in X4 Pharmaceuticals, Inc. This disclosure was made via an amended Schedule 13G filing, indicating shared voting and dispositive power over 8,085,006 shares, including …

Fuller & Thaler (NASDAQ: COLL) reports 5.03% beneficial stake in common stock

Fuller & Thaler Asset Management, Inc. has reported a beneficial ownership of 5.03% in COLLEGIUM PHARMACEUTICAL, INC (COLL) common stock, totaling 1,632,780.71 shares as of June 30, 2026. The firm holds sole voting and dispositive power over these shares, which are held in accounts …

Liminatus Pharma (LIMN) logs $2.5M loss and fights Nasdaq listing threats

Lyell Immunopharma (LYEL): Foresite funds and Tananbaum report 2.7% ownership

Foresite Capital-affiliated funds and James B. Tananbaum have reported a beneficial ownership of 653,328 shares of Lyell Immunopharma (LYEL) common stock, representing 2.7% of the class. This disclosure was made in an updated SCHEDULE 13G/A SEC filing. The ownership is primarily held by Foresite …

Phio Pharmaceuticals Corp. SEC Filing (Aug 14, 2026)

This article reports on an SEC filing (Form ARS) by Phio Pharmaceuticals Corp. (PHIO) on August 14, 2026. The filing has a low impact and neutral sentiment, and the document is available as a PDF. The article also provides recent news and other SEC …

RA Capital boosts Karyopharm (KPTI) stake to 9.99% beneficial ownership cap

RA Capital Management, L.P. and its affiliated reporting persons have reported a 9.99% beneficial ownership stake in Karyopharm Therapeutics Inc. (KPTI) as of June 30, 2026. This stake, totaling 2,302,504 shares, is held through RA Capital Healthcare Fund, L.P., and is capped at 9.99% …

RA Capital discloses 6.2% BioCryst (BCRX) holding of 15.8M shares

RA Capital Management, L.P. and its affiliated entities have reported a passive ownership stake of 6.2% in BioCryst Pharmaceuticals, Inc. This holding, as of June 30, 2026, comprises 15,827,186 shares of common stock, with RA Capital Healthcare Fund, L.P. directly owning these shares. The …

Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress

Citius Pharmaceuticals reported strong Q3 2026 financial results, including $7.1 million in commercial sales revenue for the first nine months of the fiscal year and $17 million in cash reserves. The company highlighted significant progress with its lead product, LYMPHIR, noting an 86% objective …

ADAR1 group discloses 9.9% Kiora Pharmaceuticals (KPRX) stake via shares and warrants

ADAR1 Capital Management, along with ADAR1 Capital Management GP, LLC and Daniel Schneeberger, have reported a beneficial ownership of 9.9% in Kiora Pharmaceuticals (KPRX). This stake, detailed in an amended passive investment disclosure (SCHEDULE 13G/A), includes common shares and shares underlying pre-funded and milestone …

Novo Holdings A/S (AVLN) discloses 8.8% beneficial stake in Avalyn Pharma

Novo Holdings A/S, an investment firm owned by the Novo Nordisk Foundation, has reported an 8.8% beneficial stake in Avalyn Pharma Inc. The firm holds 3,883,289 shares of Avalyn Pharma's voting common stock, with sole voting and dispositive power over these shares. The Novo …

Liminatus Pharma, Inc. Q2 2026: Net income $(1.41)M, EPS $(0.03) — 10-Q Summary

Liminatus Pharma, Inc. reported a significant consolidated net loss for Q2 2026, with net income of $(1.41)M and diluted EPS of $(0.03), contrasting with a net income in the prior year. The company highlighted key business developments, including a recent business combination, prioritization of …

Nantahala Capital discloses 9.99% Kiora Pharmaceuticals (KPRX) stake via 13G/A filing

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 9.99% in Kiora Pharmaceuticals, Inc. (KPRX) through a Schedule 13G/A filing. As of June 30, 2026, they beneficially own 491,889 shares, including those acquirable through convertible …

Nantahala Capital discloses 9.91% Eloxx Pharmaceuticals (ELOX) ownership in Schedule 13G

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, reported a 9.91% beneficial ownership stake in Eloxx Pharmaceuticals, Inc. (ELOX) through a Schedule 13G filing. As of June 30, 2026, the reporting persons beneficially own 400,000 shares, with shared voting and …

Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors

Vertex Pharmaceuticals Inc. (VRTX) stock fell 2.07% on Friday, closing at $505.75, amid a general market decline where the S&P 500 and Dow Jones Industrial Average also saw losses. This marked the third consecutive day of losses for the company's shares.

NRx Pharmaceuticals (NRXP) grows clinic revenue, flags going concern risk

GT Biopharma (NASDAQ: GTBP) wins approval for reverse split and share plan changes

GT Biopharma shareholders approved a reverse stock split, ranging from 1-for-10 to 1-for-30, and a reduction in authorized shares to 25,000,000 common and 1,500,000 preferred shares. They also approved a 3,500,000-share increase to the 2022 Omnibus Incentive Plan and an evergreen provision for automatic …

Lexicon Pharmaceuticals (LXRX) Completes Phase III Enrollment, Is The 38% Undervaluation Case Convincing?

Traws Pharma Expects Q3 Resubmission for Flu Antiviral

Ascendis Pharma A/S (NASDAQ:ASND) Releases Quarterly Earnings Results, Misses Estimates By $0.68 EPS

LB Pharmaceuticals (LBRX) investor group reports 5.0% beneficial stake in 13G/A

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu have reported a beneficial ownership of 5.0% in LB Pharmaceuticals Inc. (LBRX), totaling 1,447,310 shares, through an amended Schedule 13G filing. This ownership percentage is based on 28,676,652 shares outstanding as …

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More

The past couple of years have been volatile for Vertex Pharmaceuticals (NASDAQ: VRTX). Between clinical setbacks and worse-than-expected financial results, the company has sometimes disappointed investors. However, Vertex has always bounced back, and it recently hit a new all-time high, though it has since …

NewAmsterdam Pharma (NAMS) hires Robert Gunning as new principal accounting officer

NewAmsterdam Pharma Company N.V. (NAMS) has appointed Robert W. Gunning, 55, as its new principal accounting officer, effective August 10, 2026. Gunning will receive an annual base salary of $375,000, a target annual performance bonus of 30% of his base salary, and equity awards …

NewAmsterdam Pharma (NAMS) outlines Douglas Kling separation and advisory deal

NewAmsterdam Pharma (NAMS) has filed an amendment detailing the separation and advisory agreements with its former Chief Operating Officer, Douglas Kling, who resigned effective August 14, 2026. Kling's unvested stock options and restricted stock units will be canceled, except for those tied to continued …

Quoin Q2 Loss Hits $5.37 Million as FDA Clears Peeling Skin IND

Quoin Pharmaceuticals Ltd. (QNRX) reported a net loss of $5.37 million for the second quarter of 2026, an increase from $3.70 million in the prior year. Despite this, the company's cash position is expected to fund operations into 2027. The FDA also conditionally approved …

Processa Pharmaceuticals (NASDAQ: PCSA) lands $183M funding and Vidya BTK acquisition

ABUS|Arbutus Biopharma Corp|Price:4.710|Chg%:+0.130

Fennec Pharmaceuticals (FENC): Southpoint group files 13G/A showing 0% ownership

Southpoint-related entities and individual John S. Clark have filed an amended Schedule 13G/A for Fennec Pharmaceuticals Inc. (FENC), indicating that they now beneficially own 0 Common Shares, representing 0% of the class. This filing signifies that their ownership is 5 percent or less, with …